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Twenty seven Trp containing dipeptides were evaluated for their ability to inhibit dipeptidyl peptidase IV 
(DPP-IV), a key enzyme involved in incretin hormone processing. Novel DPP-IV inhibitors were 
identified comprising of three potent dipeptides (Trp-Arg, Trp-Lys and Trp-Leu) with half maximum 
inhibitory concentration (IC50 values) < 45 µM. With the exception of Leu-Trp which was ~20 times less 
potent than Trp-Leu, their reverse peptide did not inhibit DPP-IV. Trp-Asp was the only peptide studied 10 
herein with an N terminal Trp residue which was not a DPP-IV inhibitor. Phosphorylation resulted in an 
increase in DPP-IV IC50, giving values of 482.1 ± 12.9 and >11,000 µM for Trp-Thr and Trp-pThr, 
respectively. The mode of inhibition of these peptides was studied using Lineweaver and Burk kinetic 
analysis, which showed both competitive and non-competitive modes of inhibition depending on the 
peptide sequence. This suggested binding of the peptide inhibitors to different locations on DPP-IV. In 15 
silico analysis of the milk proteome revealed that some of the DPP-IV inhibitors identified herein may be 
released from milk proteins following enzymatic digestion. The results are relevant to understanding the 
mechanism(s) involved in DPP-IV inhibition by short peptides. This in turn may dictate a more targeted 
approach for the release of potent peptides from milk proteins with the view of developing biofunctional 
hydrolysates for the management of type 2 diabetes. 20 
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1. Introduction 
Inhibition of dipeptidyl peptidase IV (DDP-IV) by food derived 25 
constituents may represent a dietary related approach for the 
management/control of Type 2 diabetes (T2D). DPP-IV is an 
enzyme which can be found in different locations of the body 
including on the surface of various cells and in the circulation. 1 
DPP-IV has been identified to play a role in the degradation of 30 
incretin hormones such as glucose dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Those 
two incretins can enhance insulin secretion from pancreatic beta 
cells in the presence of nutrients in vivo.2 The degradation of 
GLP-1 and GIP by DDP-IV results in a loss in their bioactive 35 
properties. DPP-IV inhibitory drugs are utilized to prevent 
incretin degradation in vivo, thereby increasing their half-life.2,3 
 Binding of various competitive DPP-IV inhibitors has been 
described at the active site of DPP-IV, mainly through 
interactions with an hydrophobic pocket, composed of Tyr-666, 40 
Tyr-662, Val-711, Val-656 and Trp-659.4 However, a secondary 
binding site for DPP-IV inhibitors has been described for N 
terminus of the human immunodeficiency virus-1 (HIV) 
transactivator Tat. This secondary binding site is located close to 
the active site and involves linear mixed-type or parabolic mixed-45 
type inhibition of DPP-IV.5 A milk protein-derived dipeptide 
Trp-Val was recently identified, which behaved as a non-
competitive inhibitor of DPP-IV. Using a molecular docking 
approach, it was shown that Trp-Val was likely to interact with 
DPP-IV at a secondary binding site located in close proximity to 50 
the active site.6 Another mechanism of DDP-IV inhibition has 
recently been described for larger peptides (> 13 amino acid 
residues) where peptides may hinder the formation of the active 
dimer of DPP-IV.7  
 Peptide inhibitors of DPP-IV with various sequences have 55 
been reported in the literature.8 It has been suggested that 
dipeptides with the sequence Xaa-Pro, Pro-Xaa or Xaa-Ala (with 
Xaa being an amino acid residue) can act as inhibitors.9 Different 
dipeptides with a Pro residue at the C terminus have been 
identified as DPP-IV inhibitors.10 However, various peptide 60 
sequences without Pro have also been reported as potent 
inhibitors.8,11 Recently, Trp and Trp-Val were identified as DPP-
IV inhibitors. In contrast, no inhibition could be seen with the 
reverse peptide Val-Trp and other dipeptides (Arg-Trp, Lys-Trp 
and Ile-Trp) with Trp at the C terminus.6,11 Another Trp 65 
containing peptide Trp-Pro was reported in a previous study for 
its DPP-IV inhibitory potential.12 
 Various studies have highlighted the possibility of using food 
as a natural source of DDP-IV inhibitors. An in silico approach 
was recently used to identify dietary proteins, including milk 70 
proteins, which could be potential precursors for peptides with 
DDP-IV inhibitory properties.8 A number of milk protein 
hydrolysates have been identified as DPP-IV inhibitors.11,13-15 
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Individual milk protein hydrolysates generated with -
lactoglobulin (-Lg)14,16-18 α-lactalbumin (α-La)18, bovine serum 
albumin (BSA)18 and lactoferrin (LF)11,18 have also been 
identified as potent DPP-IV inhibitors. 
 It has recently been shown that several Trp-containing 5 
dipeptides could inhibit xanthine oxidase (XO), a metabolic 
enzyme which has been associated with an increase in oxidative 
stress in humans.6,19 It has been demonstrated that T2D diabetes 
can be linked with an elevated oxidative status, which may cause 
endothelial injuries.20 There appears to be a limited amount of 10 
data available in the literature describing the role of Trp 
containing peptides as DPP-IV inhibitors and modulators of 
oxidative stress. In a previous study Trp containing dipeptides 
(Trp-Val and Val-Trp) have been identified for their radical 
scavenging activity and Trp-Val was shown to be a DPP-IV 15 
inhibitor.11 A more extensive study of the radical scavenging and 
DDP-IV inhibitory properties of Trp containing peptides has 
therefore been undertaken herein. The aim of this study was to 
evaluate the ability of Trp containing dipeptides to inhibit DPP-
IV activity. In addition, the potential antioxidant (radical 20 
scavenging activity) role of these peptides was studied. 
2. Material and methods 
2.1. Reagents 
The synthetic peptides Trp-Asp, Ala-Trp, Pro-Trp, Trp-Trp, Trp-
Leu, Leu-Trp, Trp-Tyr, Tyr-Trp, Trp-Asn, Trp-Lys, Trp-Gly, 25 
Gly-Trp, Trp-Glu, Glu-Trp and Trp-Ser were obtained from 
Bachem (Bubendorf, Switzerland) while Trp-Ala, Trp-Arg, Trp-
Gln, Trp-Ile, Trp-Phe, Trp-Met, Trp-Cys, Cys-Trp, Phe-Trp, Ser-
Trp, Lys-Trp, Asn-Trp and Met-Trp were from Thermo Fisher 
Scientific (Ulm, Germany) while Trp-Pro, Trp-Thr, Asp-Trp and 30 
Trp-pThr (where p represents a phosphorylated residue) were 
obtained from Genscript (Piscataway, NJ, USA). 
Tris(hydroxymethyl)aminomethane (TRIS), 2,2-diphenyl-1-
picrylhydrazyl (DPPH), 6-hydroxy-2,5,7,8-tetramethylchromane-
2-carboxylic acid (TroloxTM), Gly-Pro-pNA, diprotin A (Ile-Pro-35 
Ile), ethanol and porcine DPP-IV (≥ 10 Units.mg-1 protein) were 
obtained from Sigma Aldrich (Dublin, Ireland). HPLC grade 
water was from VWR (Dublin, Ireland). 
2.2. DPP-IV inhibition assay 
Peptides were dispersed in HPLC grade water at concentrations 40 
ranging from 1.25 × 10-2 to 1.25 mg.mL-1. The DPP-IV inhibition 
assay was carried out as described by Nongonierma and 
FitzGerald.11 Briefly, the test samples (25L) were pipetted onto 
a 96 well microplate (Sarstedt, Dublin, Ireland) containing Gly-
Pro-pNA, the reaction substrate (final concentration 0.2 mM). 45 
The negative control contained 100 mM Tris-HCl buffer pH 8.0 
(25L) and the substrate Gly-Pro-pNA. The reaction was 
initiated by the addition of DPP-IV (final concentration 0.0025 
Units.mL-1). All the reagents and samples were diluted in 100 
mM Tris-HCl buffer pH 8.0. Diprotin A was used as a positive 50 
control. Each sample was analysed in triplicate. The microplate 
was incubated at 37C for 60 min in a microplate reader (Biotek 
Synergy HT, Winoosky, VT, USA), absorbance of the released 
pNA was monitored at 405 nm. The DPP-IV half maximum 
inhibitory concentration (IC50) values were determined by 55 
plotting the percentage of inhibition as a function of the 
concentration of test compound. 
2.3. Determination of the mode of inhibition for DPP-IV 
inhibitory peptides 
Lineweaver and Burk analysis was used as per Nongonierma and 60 
FitzGerald11 to determine the mode of inhibition by DPP-IV 
inhibitory peptides. The initial rate of pNA release by DPP-IV 
from Gly-Pro-pNA was measured at different Gly-Pro-pNA 
concentrations ranging between 0.2 and 0.6 mM in the presence 
and absence of the DPP-IV peptide inhibitors at their IC50 65 
concentration. Km/ Kapp and Vmax values were determined 
from the double reciprocal plots. The mode of inhibition was 
determined by comparing Km to Kapp values and Vmax obtained 
in the presence and absence of the DPP-IV inhibitory peptide. 
2.4. DPPH radical scavenging assay 70 
The DPPH assay was used to determine the proton radical 
scavenging properties of the peptides which were dispersed in 
HPLC grade water at concentrations ranging from 1.25 × 10-3 to 
1.25 mg.mL-1. The DPPH scavenging assay was carried out 
essentially according to Nongonierma and FitzGerald.11 Briefly, 75 
the test samples (50L) were pipetted onto a 96 well microplate 
containing a DPPH (final concentration 0.088 mM) solution in 50 
% (v/v) ethanol. The microplate was incubated at 37C for 60 
min in a microplate reader, absorbance of the DPPH radical was 
monitored at 517 nm. Each sample was analysed in triplicate. 80 
Trolox was used as a positive control. Scavenging of the DPPH 
radical was determined with respect to a control containing no 
scavenger (DPPH solution added with 50 L water) as described 
by Liu et al.21 The DPPH scavenging EC50 values (concentration 
of active compound required to observe 50 % DPPH scavenging) 85 
were determined by plotting the percentage of DPPH scavenging 
as a function of the concentration of test compound. 
2.5. Statistical analysis 
Means comparison was carried out with a one way ANOVA 
followed by a Student Newman-Keuls test using SPSS (version 9, 90 
SPSS Inc., Chicago, IL, USA) at a significance level P < 0.05. 
3. Results 
3.1. DPP-IV inhibition of tryptophan containing peptides 
Of the 31 Trp containing dipeptides studied, 21 were able to 
inhibit DPP-IV of which 18 contained a Trp residue at the N 95 
terminus (Table 1). The IC50 value of the different DPP-IV 
inhibitory peptides was determined (Table 1). The most potent 
peptide studied herein was Trp-Arg with an IC50 value of 37.8 ± 
2.2 µM. Three other peptides with a similar (P ≥ 0.05) potency to 
Trp-Arg were determined, these were Trp-Lys, Trp-Leu and Trp-100 
Pro, having IC50 values of 40.6 ± 4.0, 43.6 ± 0.9 and 44.5 ± 2.0 
µM, respectively. The least potent DPP-IV inhibitor studied was 
Trp-pThr with an IC50 value > 11,000 µM (Table 1). With the 
exception of Trp-Asp, all peptides with a Trp residue at the N 
terminus were DPP-IV inhibitors. Three peptides with a Trp 105 
residue at the C terminus, Leu-Trp, Met-Trp and Ala-Trp, were 
also found to be DPP-IV inhibitors. 
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Table 1: Inhibitory concentration inducing 50 % inhibition (IC50) for dipeptidyl peptidase IV (DPP-IV) with Trp containing peptides. IC50 values are listed 
in order of decreasing inhibitory potency for the forward peptides. 
Forward peptide DPP IV IC50 (M)
* Reverse peptide DPP IV IC50 (M)
* 
Ile-Pro-Ile 3.5 ± 0.2a na na 
Trp-Arg 37.8 ± 2.2b Arg-Trp -† 
Trp-Lys 40.6 ± 4.0b Lys-Trp -† 
Trp-Leu 43.6 ± 0.9b Leu-Trp 993.4 ± 58.6j 
Trp-Pro 44.5 ± 2.0b Pro-Trp - 
Trp-Ala 92.6 ± 0.8c Ala-Trp > 6,000 
Trp-Gln 120.3 ± 1.5d Gln-Trp nd 
Trp-Ile 138.7 ± 8.0d,e Ile-Trp -† 
Trp-Asn 148.5 ± 9.3e Asn-Trp - 
Trp-Met 243.1 ± 1.8f Met-Trp 1691.4 ± 318.7k 
Trp-Tyr 281.0 ± 1.0f Tyr-Trp - 
Trp-Cys 420.0 ± 21.7g Cys-Trp - 
Trp-Thr 482.1 ± 12.9g,h Thr-Trp nd 
Trp-Trp 554.8 ± 15.1h,i na na 
Trp-Ser 643.5 ± 1.6i Ser-Trp - 
Trp-Glu > 2,000 Glu-Trp - 
Trp-Phe > 3,000 Phe-Trp - 
Trp-Gly >8,000 Gly-Trp - 
Trp-pThr > 11,000 pThr-Trp nd 
Trp-Asp - Asp-Trp - 
nd: not determined; na: not applicable. 
-: no DDP-IV inhibition 
*Values represent mean IC50 values ± confidence interval (P = 0.05) n=3 and triplicate determination. Values with different superscript letters are 5 
significantly different (P < 0.05) 
†Data taken from Nongonierma et al. 
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Fig 1: Lineweaver and Burk double reciprocal plots for dipeptidyl peptidase IV (DDP-IV) inhibition with Trp containing peptides having an half 
maximum inhibitory concentration (IC50) lower than 45 μM (a) Trp-Arg (b) Trp-Pro, (c) Trp-Lys and (d) Trp-Leu. Values are the mean of three 
determinations (n=3) ±SD. 
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Table 2: Mode of inhibition for dipeptidyl peptidase IV (DPP-IV) and 
milk derived fragments of Trp containing peptides. Peptides are listed in 
order of decreasing DPP-IV inhibitory potency for the forward peptides. 
Compound 
Type of 
inhibition* 
Milk protein fragment 
Ile-Pro-Ile competitive κ-CN (f26-28) 
Trp-Arg non-competitive LF (f24-25) 
Trp-Lys non-competitive LF (f268-269) 
Trp-Leu competitive α-La (f104-105), α-La (f118-119) 
Trp-Pro non-competitive na 
Trp-Ala non-competitive LF(f560-561) 
Trp-Gln non-competitive κ-CN (f76-77), LF f(22-23) 
Trp-Ile non-competitive αs2-CN (f193-194), LF (f125-126) 
Trp-Asn non-competitive LF (f448-449), LF (f467-468) 
Trp-Met non-competitive β-CN (f143-144) 
Trp-Tyr non-competitive β-Lg (f19-20), αs1-CN (f164-165) 
Trp-Cys non-competitive α-La (f60-61), LF (f8-9), LF (f347-348) 
Trp-Thr non-competitive LF f(138-139) 
Trp-Trp non-competitive na 
Trp-Ser non-competitive BSA f(213-214), LF (f361-362) 
Trp-Glu nd β-Lg (f61-62), LF (f549-550) 
Trp-Phe nd LF (f16-17) 
Trp-Gly nd BSA (f134-135) 
Trp-pThr nd LF f(138-139) 
Trp-Asp na αs2-CN (f109-110) 
Arg-Trp na LF (f7-8), LF (f21-22) 
Lys-Trp na β-Lg (f60-61) 
Leu-Trp competitive αs1-CN (f198-199) 
Pro-Trp na αs2-CN (f108-109), αs2-CN (f192-193) 
Ala-Trp nd BSA (f212-213), αs1-CN (f163-164) 
Gln-Trp 
na α-La (f117-118), LF (f23-24), LF (f360-
361), κ-CN (f75-76) 
Ile-Trp na α-La (f59-60), LF (f267-268) 
Asn-Trp na na 
Met-Trp nd na 
Tyr-Trp na α-La (f103-104) 
Cys-Trp na na 
Ser-Trp na LF (f137-138), β-CN (f142-143) 
Glu-Trp na α-La (f25-26), LF (f15-16) 
Phe-Trp na BSA (f133-134) 
Gly-Trp na LF (f124-125), LF (f466-467) 
Asp-Trp na LF (f559-560) 
na: not applicable; nd: not determined. 
*Type of inhibition determined using Lineweaver and Burk plots as 5 
described in Nongonierma & FitzGerald 
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CN: casein; β-Lg: beta-lactoglobulin; α-La: alphalactalbumin; LF: 
lactoferrin; BSA: bovine serum albumin. 
 
 Most of the DPP-IV peptide inhibitors studied could be found 10 
within milk protein sequences with the exception of three 
peptides (Trp-Pro, Trp-Trp and Met-Trp, Table 2). Lineweaver 
and Burk kinetic analysis was utilized to determine the type of 
DPP-IV inhibition with the most potent (IC50 values < 1000 µM, 
Table 1) peptides studied herein. The Lineweaver and Burk 15 
double reciprocal plots for Trp-Arg, Trp-Pro, Trp-Lys and Trp-
Leu are illustrated in Fig. 1. There was no significant difference 
in Vmax (P ≥ 0.05) in the presence and absence of inhibitor for 
Ile-Pro-Ile, Trp-Leu and Leu-Trp. However, the Km value was 
significantly different from Kapp values (P < 0.05). These 20 
peptides therefore behaved as competitive inhibitors of DPP-IV 
(Fig. 1 and Table 2). In contrast, for the thirteen other peptides 
(Trp-Arg, Trp-Lys, Trp-Pro, Trp-Ala, Trp-Gln, Trp-Ile, Trp-Asn, 
Trp-Met, Trp-Lys, Trp-Cys, Trp-Thr, Trp-Trp and Trp-Ser) tested 
there was no significant difference between Km and Kapp (P ≥ 25 
0.05). However, Vmax values were significantly different (P < 
0.05) in the presence and absence of inhibitor. These peptides 
therefore behaved as non-competitive inhibitors of DPP-IV 
(Table 2). 
3.2. Antioxidant activity of the peptides 30 
The antioxidant activity of the peptides was evaluated by 
determining their ability to scavenge the DPPH radical. All 
peptides evaluated were able to scavenge DPPH radicals with the 
exception of Trp-Glu (Table 3). The antioxidant potency of the 
peptides was evaluated by determining their EC50 value. A wide 35 
range of EC50 values was found. The most potent antioxidant 
peptide was Cys-Trp with an EC50 of 0.23 ± 0.10 mM. The least 
potent compound was Asp-Trp with an EC50 > 20 mM. Of the 
different antioxidant peptides identified, 21 were also DPP-IV 
inhibitory peptides (Tables 1 and 3). 40 
Table 3: Inhibitory concentration inducing 50 % scavenging (EC50) for 
the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical with Trp containing 
peptides. Peptides are listed in order of decreasing DPPH scavenging 
activity for the forward peptides. 
Forward 
peptide 
DPPH EC50 
(mM)* 
Reverse 
peptide 
DPPH EC50 
(mM)* 
Trp-Cys 0.26 ± 0.09b Cys-Trp 0.23 ± 0.10a 
Trp-Tyr 1.28 ± 0.01d Tyr-Trp 0.57 ± 0.01c 
Trp-Met - Met-Trp 2.53 ± 0.46e 
Trp-pThr 2.43 ± 0.11e pThr-Trp nd 
Trp-Pro 2.57 ± 0.03e,f Pro-Trp >10 
Trp-Leu 2.71 ± 0.03e Leu-Trp 1.71 ± 0.02d 
Trp-Gln 3.92 ± 1.29g,h,i,j Gln-Trp nd 
Trp-Phe 4.20 ± 0.27i,j,k Phe-Trp 3.04 ± 0.86e,f,g 
Trp-Arg 4.43 ± 1.03i,j,k Arg-Trp nd 
Trp-Thr 4.92 ± 0.03h,i,j Thr-Trp nd 
Trp-Asn 4.92 ± 1.13h,i,j,k Asn-Trp >5 
Trp-Lys >5 Lys-Trp 4.14 ± 0.82h,i,j 
Trp-Gly >5 Gly-Trp 3.68 ± 0.12f,g,h,i 
Trp-Ser >5 Ser-Trp 3.97 ± 0.26g,h,i,j 
Trp-Met >5 Met-Trp nd 
Trp-Ala >5 Ala-Trp > 10 
Trp-Ile >5 Ile-Trp nd 
Trp-Asp >5 Asp-Trp >20 
Trp-Trp >10 na na 
Trp-Glu - Glu-Trp 3.07 ± 0.92e,f,g 
na: not applicable.; nd: not determined. 45 
-: no inhibition 
*Values represent mean IC50 values ± confidence interval (P = 0.05) n=3 
and triplicate determination. Values with different superscript letters are 
significantly different (P < 0.05) 
EC50 values for Trolox was of 17.2 ± 5.5 nM. 50 
4. Discussion 
It has been suggested that dipeptides with a Pro residue at the C 
terminus behave as DPP-IV inhibitors.9 To date, the most potent 
(IC50 < 100 µM) DPP-IV inhibitory peptides identified in the 
literature appear to contain a Pro or a N-terminal Trp residue.8 55 
Nevertheless, relatively potent DPP-IV inhibitory peptides 
containing no Pro or Trp residues have also been reported.11,13,16 
Yamada et al. 22 studied the structure function relationship of a 
potent inhibitor isolated from Aspergillus oryzae A374 (TMC-2) 
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containing Trp and 2 unusual amino acids ((3S)-6,8-dihydroxy-7-
methoxy-l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) 
and (L)-dihydroxy-leucine). It was shown that a Trp residue 
located at the N terminus of the tripeptide resulted in highest 
DPP-IV inhibition. IC50 values of 5.7, 7.0 and 7.9 µM were 5 
reported for Trp-Tic, Trp-Tic-Glu and Trp-Tic-Ser, respectively. 
The Trp-Tic fragment of the tripeptide was shown to be 
responsible for the DPP-IV inhibitory properties of TMC2. 
Relatively low DPP-IV inhibition (≤ 15 %) was seen with Trp-
Glu, Trp-Phe, Trp-Pro, Trp-Trp, Trp-Tyr and Trp-Val when 10 
tested at 10 µM.22 The most potent peptide studied herein was 
Trp-Arg (IC50 37.8 ± 2.2 µM, Table 1). This compound has a 
potency of the same order as previously identified DPP-IV 
inhibitory peptides. IC50 values of 45, 46, 49, 66 and 82 µM for 
Ile-Pro-Ala-Val-Phe, Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu, Ile-Pro-15 
Ala, Trp-Val and Leu-Pro-Gln, respectively have been 
reported.11,13,14,17 However, the presence of Pro and/or Trp 
residues within a peptide sequence does not guarantee DPP-IV 
inhibition as demonstrated by the absence of inhibition with Pro-
Trp and the other Trp containing non-inhibitory peptides (Table 20 
1). 
 In a previous study, it was found that Trp-Val was a DPP-IV 
inhibitor whereas the reverse peptide Val-Trp was inactive. In 
addition, other dipeptides with a Trp at the C terminus (Arg-Trp, 
Lys-Trp and Ile-Trp) could not inhibit DPP-IV.11 All the 25 
dipeptides studied herein with a Trp residue at the N terminus 
(Trp-Arg, Trp-Lys, Trp-Leu, Trp-Pro, Trp-Ala, Trp-Gln, Trp-Ile, 
Trp-Asn, Trp-Tyr, Trp-Cys, Trp-Thr, Trp-Ser, Trp-Trp Trp-Glu, 
Trp-Phe, Trp-Gly and Trp-pThr) could inhibit DPP-IV with the 
exception of Trp-Asp. The reverse peptides were generally not 30 
able to inhibit DPP-IV with the exception of Leu-Trp, Met-Trp 
and Ala-Trp. However, these peptides had a relatively low 
potency (IC50 > 900 µM) which was more than ten times less than 
that of the corresponding forward peptide (Table 1). These results 
showed that sequence and not only composition is a major 35 
determinant in the DPP-IV inhibitory potential of a peptide. 
 Larger peptides with a Trp at the N terminus are also able to 
inhibit DPP-IV in the same fashion as dipeptides. However, a 
limited number of DPP-IV inhibitory Trp containing peptides 
larger than 2 amino acids appear to exist in the literature. The Trp 40 
containing peptide derived from β-lactoglobulin, Val-Ala-Gly-
Thr-Trp-Tyr, with an IC50 of 174 µM has been reported.
16 
 It was found herein that Trp-pThr could inhibit DPP-IV, 
however, the potency of this peptide was relatively low. To our 
knowledge this is the first time that a phosphorylated peptide has 45 
been evaluated for its DDP-IV inhibitory activity. The IC50 value 
of Trp-pThr (> 11,000 µM) was around 25 times more than that 
of the non-phosphorylated equivalent Trp-Thr (482.1 ± 12.9 µM), 
suggesting that phosphorylation was responsible for the decrease 
in DPP-IV inhibitory activity. This may be explained by the fact 50 
that addition of the phospo group to the dipeptide may have 
interfered with binding to DPP-IV. Binding of peptides to the 
active site of DPP-IV has been reported to involve both 
hydrophobic and electrostatic interactions.23,24 Docking of amino 
acids and peptides to the active site of DPP-IV also showed 55 
interaction of competitive inhibitors with the hydrophobic pocket 
of DPP-IV.6 The major reduction in IC50 value observed between 
Trp-pThr and Trp-Thr may arise from differences in the charge of 
the two peptides. Alterations in peptide charge may modify the 
electrostatic interaction between the peptide and its binding site 60 
on DPP-IV. This may have led to higher electrostatic repulsion 
between Trp-pThr and DPP-IV, causing a reduction in the DPP-
IV inhibitory properties. 
 Different modes of DPP-IV inhibition were found with the 
peptides evaluated herein. Most Trp containing peptides were 65 
found to be non-competitive inhibitors of DPP-IV (Table 2). The 
two competitive Trp containing DPP-IV inhibitors, Leu-Trp and 
Trp-Leu, presumably bind to the active site of DPP-IV. Trp-Pro 
was described elsewhere as a DPP-IV inhibitor with a linear 
mixed-type mode of inhibition.12 This is in agreement with the 70 
results reported herein since non-competitive inhibition has been 
described as a specific case of mixed-type inhibition. Non-
competitive inhibition suggests interaction with DPP-IV at a 
different location from the active site. Similar results have 
previously been reported with Trp-Val which also behaved as a 75 
non-competitive inhibitor of DPP-IV. In addition, utilisation of 
the Pepsite2 tool showed that Trp-Val was likely to bind near the 
active site of DPP-IV.6 Other studies have shown that linear 
mixed-type or parabolic mixed-type inhibitors, including peptides 
derived from the N terminus of the HIV transactivator Tat, could 80 
bind to a secondary site near the active site of DPP-IV.5 More 
knowledge on the secondary binding site of DPP-IV is needed to 
understand binding of inhibitors at this site. This may allow 
enhanced prediction and discovery of potent DPP-IV inhibitory 
peptide sequences. 85 
 The peptides evaluated herein had a modest DPPH scavenging 
activity compared to other peptides mentioned in other studies. 
EC50 values for DPPH scavenging by decapeptides extracted 
from venison were around 10 M25, 98 M for the casein derived 
peptide Tyr-Pro-Tyr-Pro-Glu-Leu and 23 M for carnosine (Ala-90 
His).26 EC50 values of 0.24 and 0.65 mM have been reported for 
Trp-Val and Val-Trp, respectively.11 The most potent DPPH 
scavengers studied herein were Cys-Trp and Trp-Cys. The 
presence of Cys may be responsible for the antioxidant activity in 
these peptides. This is linked to the fact that Cys can reduce the 95 
DPPH radical.27,28 It has been suggested that the antioxidant 
property of dipeptides depends on peptide sequence rather than 
its composition. A stronger antioxidant activity has been reported 
for Trp-Lys compared to Lys-Trp.29 Similarly, for all peptides, 
differences were seen between the forward and the reverse 100 
peptide for DPPH scavenging (Table 3). In general, higher DPPH 
EC50 values were found with dipeptides having a Trp residue 
located at the N terminus compared to the reverse peptide. 
However, for Trp-Asp and Trp-Ala, DPPH EC50 was lower than 
that of their corresponding reverse peptide (Table 3). 105 
Interestingly, the phosphorylated peptide Trp-pThr, which had an 
EC50 value of 2.43 ± 0.11 mM, was twice as potent as the non-
phosphorylated peptide, Trp-Thr (EC50 of 4.92 ± 1.13 mM, Table 
3). 
 Most of the peptides evaluated herein had a dual bioactivity 110 
combining antioxidant and DPP-IV inhibitory properties (Tables 
1 and 3). In addition, some of the peptides studied herein have 
already been reported with other bioactive properties. Trp-Trp, 
Trp-Leu, Ile-Trp, Trp-Val, Ala-Trp30, Trp-Pro, Trp-Thr, Trp-
pThr31, Trp-Tyr32 and Trp-Gly33 have been identified as 115 
angiotensin converting enzyme (ACE) inhibitors. Combined ACE 
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and DPP-IV inhibitory properties of peptides are highly relevant 
to the management of T2D as cardiac complications have been 
associated with many TD2 cases.9 
 With the exception of 3 peptides, all the DDP-IV inhibitory 
peptides studied herein could be found within the primary 5 
sequence of different milk proteins (Table 2). This demonstrates 
that milk proteins could be a good source for such peptides, 
especially since milk protein hydrolysates have been identified 
for their DPP-IV inhibitory properties. The most potent peptides 
Trp-Arg and Trp-Lys can be found within LF and Trp-Leu within 10 
α-La, suggesting that whey proteins are a good source for these 
DPP-IV inhibitory Trp containing peptides (Table 1 and 2). 
Previous studies have identified an LF hydrolysate with potent 
DPP-IV inhibitory activity having an IC50 of 1.088 ± 0.106 
mg.ml-1.11 In silico digestion of LF with the Peptide Cutter 15 
programme34 showed that two peptides with a Trp at the N 
terminus (Trp-Gln-Trp-Arg and Trp-Cys-Thr-Ile-Ser-Gln-Pro-
Glu-Trp-Phe-Lys) could theoretically be released after incubation 
with trypsin. The LF hydrolysate described earlier was generated 
with trypsin. It is likely that these 2 peptides with a Trp at their N 20 
terminus are DPP-IV inhibitors based on the results presented 
herein and on previous data from the literature.12,22 Therefore, it 
is anticipated that these peptides may contribute to the overall 
DPP-IV inhibitory activity observed with the LF hydrolysate. 
 It is generally accepted that short peptides are relatively stable 25 
to gastrointestinal digestion. The intestinal stability of Trp 
containing dipeptides was predicted using the model developed 
by Foltz et al.35 It was shown that Trp-Val was moderately stable 
to intestinal digestion (between 25 to 75 % of intact peptide 
remaining after 60 min simulated intestinal digestion), whereas 30 
other Trp containing dipeptides (Arg-Trp, Lys-Trp, Val-Trp and 
Ile-Trp) were not predicted to be stable.6 Based on these results, it 
is anticipated that certain Trp containing dipeptides studied herein 
may survive gatrointestinal digestion. In addition, some of these 
peptides may be bioavailable. Permeation of di- and tripeptides 35 
through intestinal mucosa models consisting of Caco-2 cells has 
been demonstrated.36,37 Recently, it was shown that Trp 
containing short peptides derived from lactoferricin B (Trp-Gln 
and Arg-Trp-Gln), could cross Caco-2 cell monolayers. 38 The 
bioavailaibilty of short peptides has also been reported in 40 
humans. It has been shown that short peptides (Leu-Trp, Phe-Tyr, 
Ile-Trp and Ile-Pro-Pro) could be found intact in the circulation of 
humans following the consumption of a drink enriched with the 
lactotripeptide Ile-Pro-Pro.39 In addition, a relatively long half-
time of 2.3 h was reported for Trp-Gln in human plasma.38 45 
Because DPP-IV is an ubiquitous enzyme and the incretin 
hormones GLP-1 and GIP have a systemic target (i.e., the 
pancreas), the bioavailability of DPP-IV inhibitory Trp 
containing peptides is highly relevant in strategies aiming to 
increase incretin half-life in vivo. Enzymatic strategies to 50 
specifically release peptides with a Trp residue at the N terminus 
may allow development of potent DPP-IV inhibitory 
hydrolysates. This approach may find application in the 
development of functional foods with serum glucose lowering 
activity. There is a need for in vivo studies to validate these 55 
findings. 
Conclusion 
New and potent DPP-IV inhibitory peptides with a Trp at the N 
terminus have been reported. In general, the reverse peptides 
were not able to inhibit DPP-IV or had a significantly reduced 60 
potency compared to the forward peptide. Interestingly, both 
competitive and non-competitive modes of inhibition were found 
depending on peptide sequence, suggesting both direct interaction 
of the inhibitor with the active site of DPP-IV and binding at a 
secondary site. More detailed knowledge of DPP-IV binding sites 65 
may help to better understand the physicochemical properties of 
peptides which may positively impact on DPP-IV inhibition. 
Several of the peptides studied herein were found within the milk 
proteome, suggesting that these may be enzymatically released 
from milk proteins. However, other Trp-rich food proteins may 70 
also be used as starting substrates for the generation of 
hydrolysates with potent DPP-IV inhibitory properties. The 
targeted release of peptides with a Trp residue at the N terminus 
may be relevant for the generation of food protein hydrolysates 
with an antidiabetic biofunctionality. 75 
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